Form 4: Marinus Pharmaceuticals Director Sells Shares to Cover Tax Obligations

Director Elan Ezickson sold 1,600 shares of Marinus Pharmaceuticals common stock on January 21, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• On January 21, 2025, Elan Ezickson, a director of Marinus Pharmaceuticals, Inc., sold 1,600 shares of common stock.
• The sale was executed at a price of $0.54 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 10, 2024.
• The purpose of the sale was to cover tax obligations associated with the vesting of restricted stock units.
• Following the transaction, Ezickson directly owns 10,900 shares of Marinus Pharmaceuticals.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction appears to be a routine sale of shares for tax purposes under a pre-arranged plan.

Industry Context

Sales by company insiders are a common occurrence, often related to personal financial planning or tax obligations. The use of a 10b5-1 plan suggests the insider planned the transaction in advance.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, but the pre-planned nature of the sale mitigates this concern.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Elan Ezickson, Form 4, Share Sale, Director, Rule 10b5-1 Plan, Tax Obligations, Restricted Stock Units